HOHCells

Executive Summary

HOHCells is a San Diego-based biotechnology company developing advanced cryopreservation solutions to address a critical bottleneck in cell therapy and regenerative medicine. Its flagship product, FreezOpt™, is a proprietary ice nucleation system that dramatically improves post-thaw cell viability and recovery for stress-sensitive cells such as stem cells and immune cells. By enabling more reliable and scalable cell preservation, HOHCells aims to support the growing demand for high-quality cell products in research and clinical applications. The company targets a significant market need, as current cryopreservation methods often result in low viability and functional loss, particularly for complex cell types. FreezOpt™ has the potential to enhance manufacturing efficiency and reduce costs for cell therapy developers, making it a key enabler for the broader adoption of cell-based treatments. With a focus on regulatory compliance and scalability, HOHCells is well-positioned to partner with pharmaceutical companies and contract manufacturers seeking robust preservation solutions. The company's technology could also expand the viability of cell-based therapies for indications requiring off-the-shelf availability.

Upcoming Catalysts (preview)

• Q3 2026Commercial launch of FreezOpt™70% success
• Q4 2026Strategic partnership with a leading cell therapy developer60% success
• Q2 2026Series A financing round80% success